Literature DB >> 11154982

Factors influencing effectiveness of deferiprone in a thalassaemia major clinical setting.

G C Del Vecchio 1, E Crollo, F Schettini, F Schettini, R Fischer, D De Mattia .   

Abstract

The effectiveness of deferiprone (L1) and the influence of other factors were determined in a clinical setting. Patients of Southern Italian origin, affected by beta-thalassaemia major (n = 13: 7 M, 6 F), aged 10-28 years (median 18 years), were treated with L1 within a 'Controlled Programme' of the Italian Ministry of Health. Desferrioxamine could not be administered in these patients because of anaphylactic reactions or other serious side effects. L1 was considered to be effective when the liver iron concentration was reduced or stable as measured by biomagnetic liver susceptometry. L1 proved to be effective in 3 out the 9 evaluable patients. A high pre-L1 iron overload was the main clinical factor influencing L1 effectiveness.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11154982     DOI: 10.1159/000039759

Source DB:  PubMed          Journal:  Acta Haematol        ISSN: 0001-5792            Impact factor:   2.195


  3 in total

Review 1.  Clinical research: a tale of two studies.

Authors:  David G Nathan
Journal:  Trans Am Clin Climatol Assoc       Date:  2003

2.  Interactions of the pyridine-2-carboxaldehyde isonicotinoyl hydrazone class of chelators with iron and DNA: implications for toxicity in the treatment of iron overload disease.

Authors:  Timothy B Chaston; Des R Richardson
Journal:  J Biol Inorg Chem       Date:  2003-02-05       Impact factor: 3.358

3.  Single-center retrospective study of the effectiveness and toxicity of the oral iron chelating drugs deferiprone and deferasirox.

Authors:  Nancy F Olivieri; Amir Sabouhanian; Brenda L Gallie
Journal:  PLoS One       Date:  2019-02-27       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.